STAT News article on Constellation's pan BET inhibitor

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

STAT News article on Constellation's pan BET inhibitor

posted on Jun 16, 2020 10:11AM

https://www.statnews.com/2020/06/12/as-efficacy-of-constellations-blood-cancer-drug-wanes-the-debate-over-its-future-ratchets-higher/

Might be STAT+ access only. Some debate about the efficacy and safety of Constellation's CPI-0610 pan BET inhibitor from its Phase 2 trial. They are gearing up for Phase 3. This is for blood cancer, not prostate or breast cancer.